Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2018 Filed Jun 20, 2018 20:35 UTC |
Macdonald R. LochDirector
|
GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021589 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:27 UTC |
Spiegel Robert J.Director
|
GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021580 · form4.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:54 UTC |
Ratcliffe LiamDirector
|
GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021621 · form4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:39 UTC |
Marchio Albert N IIChief Accounting & Adm Officer
|
GrantStock Option (Right To Purchase) · Derivative | 83,334 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021594 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 83,334 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:37 UTC |
BARER SOL JDirector
|
GrantStock Option (Right To Purchase) · Derivative | 40,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021592 · form4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:30 UTC |
Crane Rosemary ADirector
|
GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021584 · form4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:28 UTC |
LOUGHLIN JAMES JDirector
|
GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021582 · form4.xml · derivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:19 UTC |
Saik AndrewChief Financial Officer
|
GrantStock Option (Right To Purchase) · Derivative | 166,001 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021571 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,001 Underlying: Common Stock · 166,001 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:15 UTC |
MIDDLEKAUFF W BRADFORDSenior VP, GC and Secretary
|
GrantStock Option (Right To Purchase) · Derivative | 99,534 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021564 · form4.xml · derivative · entry 1 MIDDLEKAUFF W BRADFORD · CIK 0001214501 · Senior VP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,534 Underlying: Common Stock · 99,534 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:12 UTC |
Wyant AlyssaSVP Regulatory Affairs
|
GrantStock Option (Right To Purchase) · Derivative | 99,534 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021562 · form4.xml · derivative · entry 1 Wyant Alyssa · CIK 0001698765 · SVP Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,534 Underlying: Common Stock · 99,534 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 09:22 UTC |
BLECH ISAACDirector
|
GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021660 · form4.xml · derivative · entry 1 BLECH ISAAC · CIK 0000905536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| March 23, 2018 Filed Mar 30, 2018 23:19 UTC |
Conti Kurt GDirector
|
OtherCommon Stock | 58,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-013142 · form4.xml · nonDerivative · entry 1 Conti Kurt G · CIK 0001653204 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: On March 23, 2018 three Trusts were dissolved and share ownership of 58,476 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to the Reporting Person's three adult children who do not live in the same household as Reporting Person. F2 · ownership.direct: On March 23, 2018 the Austin Conti Trust was dissolved and share ownership of 29,238 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to sole ownership of Austin Conti, the Reporting Person's adult child who does not live in the same household as Reporting Person. F3 · ownership.direct: On March 23, 2018 the Brooke Conti Trust was dissolved and share ownership of 14,619 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to sole ownership of Brooke Conti, the Reporting Person's adult child who does not live in the same household as Reporting Person. F4 · ownership.direct: On March 23, 2018 the Hunter Conti Trust was dissolved and share ownership of 14,619 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to sole ownership of Hunter Conti, the Reporting Person's adult child who does not live in the same household as Reporting Person. F2 · ownership.nature: On March 23, 2018 the Austin Conti Trust was dissolved and share ownership of 29,238 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to sole ownership of Austin Conti, the Reporting Person's adult child who does not live in the same household as Reporting Person. F3 · ownership.nature: On March 23, 2018 the Brooke Conti Trust was dissolved and share ownership of 14,619 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to sole ownership of Brooke Conti, the Reporting Person's adult child who does not live in the same household as Reporting Person. F4 · ownership.nature: On March 23, 2018 the Hunter Conti Trust was dissolved and share ownership of 14,619 shares of common stock for which the Reporting Person had previously disclaimed beneficial ownership of transferred to sole ownership of Hunter Conti, the Reporting Person's adult child who does not live in the same household as Reporting Person. Read SEC document |
| March 22, 2018 Filed Mar 22, 2018 20:03 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 2,500 | $16.41 | $41,025.00 |
DisclosureSEC source: 0001127602-18-012504 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.56 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2018 Filed Mar 21, 2018 15:34 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 2,500 | $16.52 | $41,300.00 |
DisclosureSEC source: 0001127602-18-012359 · form4.xml · nonDerivative · entry 3 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,102 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.42 to $16.58 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 15:34 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $16.47 | $82,350.00 |
DisclosureSEC source: 0001127602-18-012359 · form4.xml · nonDerivative · entry 2 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.86 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 15:34 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 2,500 | $16.66 | $41,650.00 |
DisclosureSEC source: 0001127602-18-012359 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.97 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 08:19 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $15.08 | $37,700.00 |
DisclosureSEC source: 0001127602-18-009804 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.79 to $15.31 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 08:19 UTC |
Leuthner Brian ADirector · President and CEO
|
GrantStock Option (Right To Purchase) · Derivative | 280,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009804 · form4.xml · derivative · entry 5 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2028-03-01 F6 · derivative.exercise_date: This option, representing a right to purchase a total of 280,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 08:19 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $14.81 | $37,025.00 |
DisclosureSEC source: 0001127602-18-009804 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.29 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 08:31 UTC |
Faleck Herbert JChief Medical Officer
|
GrantStock Option (Right To Purchase) · Derivative | 90,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009820 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 90,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 18:56 UTC |
MIDDLEKAUFF W BRADFORDSenior VP, GC and Secretary
|
GrantStock Option (Right To Purchase) · Derivative | 65,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009885 · form4.xml · derivative · entry 1 MIDDLEKAUFF W BRADFORD · CIK 0001214501 · Senior VP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 65,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:29 UTC |
BRENNAN DANIELChief Operating Officer
|
GrantStock Option (Right To Purchase) · Derivative | 90,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009817 · form4.xml · derivative · entry 1 BRENNAN DANIEL · CIK 0001657999 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 90,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:27 UTC |
Saik AndrewChief Financial Officer
|
GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009814 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 50,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:22 UTC |
Marchio Albert N IIChief Accounting & Adm Officer
|
GrantStock Option (Right To Purchase) · Derivative | 25,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009808 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 25,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:24 UTC |
Wyant AlyssaSVP Regulatory Affairs
|
GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009811 · form4.xml · derivative · entry 1 Wyant Alyssa · CIK 0001698765 · SVP Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 50,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| February 23, 2018 Filed Feb 23, 2018 17:28 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $15.37 | $38,425.00 |
DisclosureSEC source: 0001127602-18-008091 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.92 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2018 Filed Feb 22, 2018 22:00 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 2,500 | $14.49 | $36,225.00 |
DisclosureSEC source: 0001127602-18-007774 · form4.xml · nonDerivative · entry 3 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,102 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.23 to $14.76 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 17:28 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $15.47 | $38,675.00 |
DisclosureSEC source: 0001127602-18-008091 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.75 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 22:00 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $13.82 | $69,100.00 |
DisclosureSEC source: 0001127602-18-007774 · form4.xml · nonDerivative · entry 2 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.68 to $14.05 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:00 UTC |
Macdonald R. LochDirector · Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $13.75 | $68,750.00 |
DisclosureSEC source: 0001127602-18-007774 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.66 to $13.86 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2018 Filed Feb 2, 2018 21:15 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $12.96 | $32,400.00 |
DisclosureSEC source: 0001127602-18-003874 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $12.78 to $13.06 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 21:15 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $13.14 | $32,850.00 |
DisclosureSEC source: 0001127602-18-003874 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $12.68 to $13.45 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2018 Filed Jan 3, 2018 18:48 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.11 | $25,275.00 |
DisclosureSEC source: 0001127602-18-000813 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.21 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 18:48 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.11 | $25,275.00 |
DisclosureSEC source: 0001127602-18-000813 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.45 to $10.45 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 18:53 UTC |
Faleck Herbert JChief Medical Officer
|
GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-18-000822 · form4.xml · derivative · entry 1 Faleck Herbert J · CIK 0001652994 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-02 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 23:50 UTC |
Marchio Albert N IIChief Accounting & Adm Officer
|
GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-18-000817 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-02 Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 17:39 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $9.68 | $24,200.00 |
DisclosureSEC source: 0001127602-17-033971 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.46 to $9.87 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 17:39 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $9.97 | $24,925.00 |
DisclosureSEC source: 0001127602-17-033971 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.37 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:39 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $9.92 | $24,800.00 |
DisclosureSEC source: 0001127602-17-033971 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.06 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2017 Filed Nov 22, 2017 20:08 UTC |
Marchio Albert N IIChief Accounting & Adm Officer
|
SaleCommon Stock | 3,361 | $10.00 | $33,610.00 |
DisclosureSEC source: 0001127602-17-033177 · form4.xml · nonDerivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 03, 2017 Filed Nov 3, 2017 17:53 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.86 | $27,150.00 |
DisclosureSEC source: 0001127602-17-031249 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.02 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2017 Filed Nov 3, 2017 17:53 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.94 | $27,350.00 |
DisclosureSEC source: 0001127602-17-031249 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $11.08 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 17:53 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.92 | $27,300.00 |
DisclosureSEC source: 0001127602-17-031249 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.40 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 22:03 UTC |
Saik AndrewChief Financial Officer
|
GrantStock Option (Right To Purchase) · Derivative | 200,000 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001127602-17-031259 · form4.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-11-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 200,000 shares of Common Stock, will become exercisable on October 31, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| October 04, 2017 Filed Oct 4, 2017 17:52 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $11.14 | $27,850.00 |
DisclosureSEC source: 0001127602-17-029259 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $11.07 to $11.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2017 Filed Oct 4, 2017 17:52 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.93 | $27,325.00 |
DisclosureSEC source: 0001127602-17-029259 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.09 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 17:52 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.81 | $27,025.00 |
DisclosureSEC source: 0001127602-17-029259 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $10.90 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 13:08 UTC |
Crane Rosemary ADirector
|
GrantStock Option (Right To Purchase) · Derivative | 30,000 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0001127602-17-027793 · form4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-09-18 F1 · derivative.exercise_date: One third of the option shares vest upon each of the first, second, and third anniversaries of the Transaction Date. Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 20:01 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $10.31 | $25,775.00 |
DisclosureSEC source: 0001127602-17-027107 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.56 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:01 UTC |
Leuthner Brian ADirector · President and CEO
|
SaleCommon Stock | 2,500 | $9.94 | $24,850.00 |
DisclosureSEC source: 0001127602-17-027107 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.81 to $10.18 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.